Alnylam Pharmaceuticals (ALNY) Stock
Commercial RNA developer with approved rare disease medicines. Here's the price, business snapshot, and what's worth knowing about Alnylam Pharmaceuticals in August 2026.
Alnylam Pharmaceuticals (ALNY) is a biotechnology company that develops RNA interference (RNAi) therapeutics to silence disease-causing genes. Investors should know it has moved from research-stage to a commercial entity, with multiple approved medicines for rare genetic disorders — including treatments for hereditary ATTR amyloidosis, acute hepatic porphyria and primary hyperoxaluria — and a broad pipeline built on its GalNAc delivery platform. The business is growth-oriented: revenues depend on uptake of marketed drugs, pricing and successful launches of late-stage candidates. Key risks include trial outcomes, regulatory decisions, pricing pressures, manufacturing scale-up and competition from other modalities. With a market capitalisation near $62.13 billion, Alnylam may appeal to investors seeking exposure to innovative therapeutics, but it suits those comfortable with biotech volatility. This is general information for educational purposes only and not personalised investment advice; values can fall as well as rise.
Why It’s Moving
ALNY rebounds as fresh analyst coverage offsets lingering worry over recent guidance cuts.
- BMO Capital Markets initiated coverage with an outperform view, adding fresh support for the stock after the recent selloff and signaling renewed confidence in Alnylam’s pipeline story.
- Wells Fargo trimmed its price target while keeping an equal-weight stance, reflecting a more cautious read on near-term execution even as broader analyst sentiment remains constructive.
- The stock is still digesting July’s guidance cut tied to ATTR-CM market headwinds, so traders are weighing longer-term pipeline potential against softer near-term revenue visibility.
ALNY rebounds as fresh analyst coverage offsets lingering worry over recent guidance cuts.
- BMO Capital Markets initiated coverage with an outperform view, adding fresh support for the stock after the recent selloff and signaling renewed confidence in Alnylam’s pipeline story.
- Wells Fargo trimmed its price target while keeping an equal-weight stance, reflecting a more cautious read on near-term execution even as broader analyst sentiment remains constructive.
- The stock is still digesting July’s guidance cut tied to ATTR-CM market headwinds, so traders are weighing longer-term pipeline potential against softer near-term revenue visibility.
Sixth Month Growth Performance
When is the next earnings date for ALNYLAM PHARMACEUTICALS INC (ALNY)?
The next expected earnings date for ALNY is October 29, 2026, though the company has not yet officially confirmed it. This report is expected to cover Q3 2026 results. Based on ALNY’s historical cadence, the date is typically set for late October.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Alnylam Pharmaceuticals' stock, with a target price of $329.08, indicating growth potential.
Financial Health
Alnylam Pharmaceuticals is performing well with strong profits and revenue, supported by healthy cash flow.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
RNAi platform potential
Alnylam’s GalNAc delivery platform enables targeted gene silencing across liver-related diseases, which could drive long-term growth, though clinical and commercial execution matters.
Clinical catalysts ahead
Late-stage trial readouts and new approvals can be material share-price catalysts; remember that trial or regulatory setbacks can also move the stock substantially.
Rare-disease reach
Market opportunity centres on rare, high‑need conditions where few therapies exist, but pricing, access and competition will influence commercial outcomes.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
